{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:19Z","timestamp":1790716579565,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["852002028"],"award-info":[{"award-number":["852002028"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.radonc.2026.111726","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:46:24Z","timestamp":1786171584000},"page":"111726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial"],"prefix":"10.1016","volume":"223","author":[{"given":"Anouk M.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur T.J.","family":"van der Boog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6279","authenticated-orcid":false,"given":"Dani\u00eblle B.P.","family":"Eekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom C.G.","family":"Budiharto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Lagerwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-8920","authenticated-orcid":false,"given":"Anna M.E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1313-5513","authenticated-orcid":false,"given":"Fia","family":"Cialdella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Dankbaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Kleynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle E.P.","family":"Philippens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J.","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Y.F.L.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-6196","authenticated-orcid":false,"given":"Pierre A.","family":"Robe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-3895","authenticated-orcid":false,"given":"Szabolcs","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-0793","authenticated-orcid":false,"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.radonc.2026.111726_b0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111726_b0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111726_b0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"issue":"11","key":"10.1016\/j.radonc.2026.111726_b0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-008-9689-z","article-title":"Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma","volume":"91","author":"Minniti","year":"2009","journal-title":"J Neurooncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111726_b0030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11060-018-2932-3","article-title":"Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)","volume":"140","author":"Mallick","year":"2018","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-8140(03)00206-8","article-title":"A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma","volume":"68","author":"Phillips","year":"2003","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111726_b0045","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2026.111726_b0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111726_b0055","doi-asserted-by":"crossref","unstructured":"Khan, L., et al., External beam radiation dose escalation for high grade glioma. Cochrane Database Syst Rev, 2016(8): p. Cd011475.","DOI":"10.1002\/14651858.CD011475.pub2"},{"issue":"11","key":"10.1016\/j.radonc.2026.111726_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257384","article-title":"Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis","volume":"16","author":"Melo","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111726_b0065","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3389\/fonc.2019.01017","article-title":"Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis","volume":"9","author":"Liao","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13014-020-01584-6","article-title":"Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis","volume":"15","author":"Trone","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13014-019-1389-7","article-title":"Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged\u2009\u2265\u200975\u2009years","volume":"14","author":"Ohno","year":"2019","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2026.111726_b0080","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ijrobp.2017.03.037","article-title":"Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial","volume":"98","author":"Guedes de Castro","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.radonc.2026.111726_b0085","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","article-title":"Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma","volume":"20","author":"Omuro","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3 Suppl","key":"10.1016\/j.radonc.2026.111726_b0090","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","article-title":"Radiation dose-volume effects in the brain","volume":"76","author":"Lawrence","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.radonc.2026.111726_b0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.radonc.2026.111726_b0100","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.radonc.2026.111726_b0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.radonc.2026.111726_b0110","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in Progressive Glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111726_b0115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-9-444","article-title":"Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme","volume":"9","author":"Verhoeff","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111726_b0120","unstructured":"Institute, N.C. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. 2017; Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development."},{"issue":"5","key":"10.1016\/j.radonc.2026.111726_b0125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1535-7163.MCT-10-0010","article-title":"Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression","volume":"9","author":"Bobola","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.radonc.2026.111726_b0130","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","article-title":"Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status","volume":"27","author":"Brandes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111726_b0135","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000200359","article-title":"Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3-4) Gliomas","volume":"99","author":"Flies","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.radonc.2026.111726_b0140","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.radonc.2026.111726_b0145","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2026.111726_b0150","first-page":"747","article-title":"Bevacizumab for symptomatic cerebral radiation necrosis after radiation of high-grade glioma or brain metastases - when and for whom?","volume":"12","author":"Kroon","year":"2025","journal-title":"Neurooncol Pract"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:35:04Z","timestamp":1790714104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0167814026005657"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111726","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111726"}}